IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

MARCELLUSI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.966
NA - Nord America 2.064
EU - Europa 1.996
SA - Sud America 558
AF - Africa 79
OC - Oceania 36
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.700
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.920
SG - Singapore 1.497
CN - Cina 1.098
IT - Italia 821
BR - Brasile 451
HK - Hong Kong 389
RU - Federazione Russa 338
IN - India 221
VN - Vietnam 177
FR - Francia 155
BD - Bangladesh 154
NL - Olanda 136
GB - Regno Unito 135
FI - Finlandia 112
DE - Germania 88
ID - Indonesia 75
TR - Turchia 72
CA - Canada 69
KR - Corea 61
JP - Giappone 45
ES - Italia 42
MX - Messico 41
AR - Argentina 36
AU - Australia 33
IQ - Iraq 31
PK - Pakistan 28
AT - Austria 24
PL - Polonia 23
ZA - Sudafrica 20
IE - Irlanda 19
TW - Taiwan 18
EC - Ecuador 17
SE - Svezia 16
TH - Thailandia 16
CO - Colombia 14
UA - Ucraina 12
CL - Cile 11
GR - Grecia 11
JO - Giordania 11
SA - Arabia Saudita 11
KE - Kenya 10
MA - Marocco 10
VE - Venezuela 10
EG - Egitto 9
IL - Israele 8
PE - Perù 8
PH - Filippine 8
PT - Portogallo 8
AL - Albania 7
CH - Svizzera 7
DO - Repubblica Dominicana 7
DZ - Algeria 7
BG - Bulgaria 6
HU - Ungheria 6
IR - Iran 6
PS - Palestinian Territory 6
BB - Barbados 5
DK - Danimarca 5
JM - Giamaica 5
LU - Lussemburgo 5
NP - Nepal 5
PY - Paraguay 5
AE - Emirati Arabi Uniti 4
MY - Malesia 4
NO - Norvegia 4
OM - Oman 4
UY - Uruguay 4
UZ - Uzbekistan 4
AO - Angola 3
AZ - Azerbaigian 3
BE - Belgio 3
CI - Costa d'Avorio 3
GT - Guatemala 3
MO - Macao, regione amministrativa speciale della Cina 3
NI - Nicaragua 3
PA - Panama 3
TN - Tunisia 3
BO - Bolivia 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
GH - Ghana 2
GM - Gambi 2
LT - Lituania 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
QA - Qatar 2
RO - Romania 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
AG - Antigua e Barbuda 1
AM - Armenia 1
AS - Samoa Americane 1
BS - Bahamas 1
BY - Bielorussia 1
CD - Congo 1
ET - Etiopia 1
GD - Grenada 1
JE - Jersey 1
KZ - Kazakistan 1
Totale 8.688
Salva come PNG Salva come JPEG
Città #
Singapore 629
Hefei 460
San Jose 309
Hong Kong 261
Council Bluffs 202
Ashburn 195
Milan 187
Bengaluru 126
Rome 114
Dallas 104
Los Angeles 98
Beijing 97
Helsinki 94
Lauterbourg 82
Jakarta 61
Ho Chi Minh City 60
Moscow 60
Guangzhou 56
Buffalo 51
New York 50
Seoul 50
Redwood City 48
Istanbul 46
Boardman 45
São Paulo 44
Hanoi 43
Santa Clara 41
Fairfield 34
Naples 33
Cangzhou 31
Seattle 31
Tokyo 27
Florence 26
Shanghai 26
Chicago 21
Bologna 19
Sydney 19
Columbus 18
Dublin 18
Wilmington 18
London 17
Woodbridge 17
Frankfurt am Main 16
Houston 16
Chandler 15
Lappeenranta 15
Tianjin 15
Washington 15
Mumbai 14
Rio de Janeiro 14
Vienna 14
Warsaw 14
Nuremberg 13
Orem 13
Shenzhen 13
Cambridge 12
Chennai 12
Duncan 12
Hyderabad 12
Lahore 12
Madrid 12
Manchester 12
Toronto 12
Turin 12
Da Nang 11
Paris 11
Amman 10
Athens 10
Campinas 10
Nairobi 10
Nanjing 10
Princeton 10
Southend 10
Ann Arbor 9
Brooklyn 9
Heidelberg 9
Atlanta 8
Baghdad 8
Brasília 8
Genoa 8
Guayaquil 8
Johannesburg 8
Melbourne 8
Palermo 8
Phoenix 8
Salvador 8
San Francisco 8
Ascoli Piceno 7
Belo Horizonte 7
Boston 7
Central District 7
City of London 7
Dhaka 7
Glasgow 7
Montreal 7
Santiago 7
Taipei 7
The Dalles 7
Bangkok 6
Caxias do Sul 6
Totale 4.559
Salva come PNG Salva come JPEG
Nome #
Adalimumab in the treatment of immune-mediated diseases 341
anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases : focus on adalimumab 296
Screening strategy to advance HCV elimination in Italy: a cost-consequence analysis 275
Osteoporosis: Economic Burden of Disease in Italy. 233
The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases 212
Economic Impact of Schizophrenia from a Hospital and Social Security System Perspective in Italy 177
Economic burden of HPV9-related diseases: a real-world cost analysis from Italy 156
An Analysis of the Distribution of Direct Cost of Diabetes Care in Selected Districts in Italy 151
HPV Vaccination during the COVID-19 Pandemic in Italy: Opportunity Loss or Incremental Cost 143
Burden of Disease of Human Papillomavirus (HPV): Hospitalizations in the Marche and Veneto Regions. An observational study. 138
Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation 132
Economic evaluation of the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) from the national payer perspective: introduction of a new treatment to the patient journey. A simulation of three European countries 130
High costs, low quality of life, reduced survival, and room for improving treatment: an analysis of burden and unmet needs in glioma 130
Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Three European Countries. 130
Optimization of hepatitis C virus screening strategies by birth cohort in Italy 129
Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma. 122
One-Year Outcomes and Trends over Two Eras of Transcatheter Aortic Valve Implantation in Real-World Practice 121
Health and Economic Outcomes of Pembrolizumab in the Treatment of Metastatic Non-small Cell Lung Cancer (mNSCLC) and Melanoma in Italy. 121
Cost-Effectiveness Analysis of Newborn Screening for Spinal Muscular Atrophy in Italy. 120
Bilateral Salpingo-Oophorectomy Versus GnRH Analogue in the Adjuvant Treatment of Premenopausal Breast Cancer Patients: Cost-Effectiveness Evaluation of Breast Cancer Outcome, Ovarian Cancer Prevention and Treatment. 120
Hospital resource utilisation from HPV-related diseases in England: a real-world cost analysis 120
The economic burden of asthma in Italy: evaluating the potential impact of different treatments in adult patients with severe eosinophilic asthma 116
Burden of Disease of Breast Cancer in Italy: A Real-World Data Analysis. 116
Long-Term Effects of Direct-Acting Antivirals on Hepatitis C: Trends in Liver Disease-Related Hospitalisations in Italy 106
Patient adherence to and tolerability of self-administered interferon beta-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study 103
Financial Burden of Transcatheter Aortic Valve Implantation 101
Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy 100
Impact of Chronic Coronary Artery Disease and Revascularization Strategy in Patients with Severe Aortic Stenosis Who Underwent Transcatheter Aortic Valve Implantation 100
Drug Prices and Value of Oncology Drugs in Italy 99
An analysis of the social and economic costs of breast cancer in Italy 98
Cross-regional variations of Covid-19 mortality in Italy: an ecological study 97
The Impact of COVID-19 Vaccination on the Italian Healthcare System: A Scenario Analysis 97
Health Technology Assessment (HTA) sull’introduzione di coorti aggiuntive per la vaccinazione contro il meningococco con vaccini quadrivalenti coniugati in Italia = Health Technology Assessment (HTA) of the introduction of additional cohorts for anti-meningococcal vaccination with quadrivalent conjugate vaccines in Italy 97
Treatment plan comparison in acute and chronic respiratory tract diseases: an observational study of doxophylline vs. theophylline 95
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 95
The economic burden of HCV-induced diseases in Italy. A probabilistic cost of illness model 93
Le implicazioni economiche delle vaccinazioni: una revisione sistematica delle valutazioni economiche e di HTA condotte in Italia [The economic value of vaccinations: a systematic review of Italian economic evaluations and HTA reports] 90
Economic Consequences of Anti-HCV Treatment of Patients Diagnosed Through Screening in Italy: A Prospective Modelling Analysis 90
Economic evaluation of spondyloarthritis: economic impact of diagnostic delay in Italy 89
R versus D, from knowledge creation to value appropriation: Ownership of patents filed by European biotechnology founders 89
Economic burden of diverticular disease: An observational analysis based on real world data from an Italian region 88
The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries 88
Analisi dei costi associati ai pazienti con diabete di tipo 2 a rischio di malattia cardiovascolare aterosclerotica o con malattia cardiovascolare aterosclerotica accertata = Economic burden of diabetic patients with established atherosclerotic cardiovascular disease or risk factors for atherosclerotic cardiovascular disease 87
Addressing HCV Elimination Barriers in Italy: Healthcare Resource Utilization and Cost Impact Using 8 Weeks' Glecaprevir/Pibrentasvir Therapy 82
One-Year Outcomes after Surgical versus Transcatheter Aortic Valve Replacement with Newer Generation Devices 79
Novel Health Economic Evaluation of a Vaccination Strategy to Prevent HPV-related Diseases: The BEST Study 78
La vaccinazione universale dei bambini contro l’influenza con il vaccino Vaxigrip Tetra® in Italia : risultati di una valutazione di Health Technology Assessment (HTA) [The universal influenza vaccination in children with Vaxigrip Tetra® in Italy: an evaluation of Health Technology Assessment]. 78
Economic burden of schizophrenia in Italy: a probabilistic cost of illness analysis 77
Budget impact analysis resulting from the use of dabigatran etexilate in preventing stroke in patients with non-valvular atrial fibrillation in Italy 77
Direct and Indirect Costs of Immunoglobulin Replacement Therapy in Patients with Common Variable Immunodeficiency (CVID) and X-Linked Agammaglobulinemia (XLA) in Italy. 77
Human papillomavirus in Italy: retrospective cohort analysis and preliminary vaccination effect from real-world data 77
Population-based frequency assessment of HPV-induced lesions in patients with borderline Pap tests in the Emilia-Romagna Region: the PATER study 75
Rationale and budget impact of bimonthly use of Cetuximab in patients with recurrent and/or metastatic head and neck cancer. 74
Impact of HPV vaccination: health gains in the Italian female population. 70
Costi diretti e indiretti assorbiti dalle patologie HCV-indotte in Italia: stima basata su una metodologia probabilistica di Cost of Illness 70
Expression of stemness genes in primary breast cancer tissues: the role of SOX2 as a prognostic marker for detection of early recurrence 70
Model of management (Mo.Ma) for the patient with schizophrenia: crisis control, maintenance, relapse prevention, and recovery with long-acting injectable antipsychotics (LAIs) 68
The direct and indirect cost of diabetes in Italy: a prevalence probabilistic approach 68
Probabilistic cost-effectiveness analysis of controlled ovarian stimulation with recombinant FSH plus recombinant LH vs. human menopausal gonadotropin for women undergoing IVF. 65
Hospital costs incurred by the Italian National Health Service for invasive cervical cancer 64
Public–private contribution to biopharmaceutical discoveries: a bibliometric analysis of biomedical research in UK 63
Channels and processes of knowledge transfer: How does knowledge move between university and industry? 63
Economics of Headache 62
Pilot evaluation of indirect costs and the impact of bipolar disorder type I 61
Governance of preventive Health Intervention and On time Verification of its Efficiency: the GIOVE Study 60
Terapia oralevsterapia infusionale nel trattamento del cancro del colon retto localmente avanzato o avanzato Analisi di minimizzazione dei costi presso una struttura ospedaliera della Regione Lazio : Analisi di minimizzazione dei costi presso una struttura ospedaliera della Regione Lazio = Oral vs injection therapy in the treatment of metastatic colorectal cancer. A cost minimization analysis in a public hospital of the Lazio region 59
Health utilities lost and risk factors associated with HPV-induced diseases in men and women. The HPV Italian collaborative study group 58
Quality of life and emotional distress in early stage and locally advanced cervical cancer patients: A prospective, longitudinal study 58
Multiple sclerosis in Italy: cost-of-illness study 58
Oxygen-Enriched Olive-Oil Dressing in Moderate-Degree Pediatric Burns: Impact on Care and Budget over a 4-Year Period in a Tertiary Children’s Hospital 58
Health Technology Assessment (HTA) e valutazione economica in sanità 58
Estimation of the number of HCV-positive patients in Italy 58
Valutazione economica dei programmi di screening contro il cancro del colon retto: evidenze indirette di lungo periodo e sostenibilita` finanziaria in un'ottica di programmazione regionale [Economic evaluation of a colorectal cancer screening program: Indirect evidence on long-term outcomes and economic sustainability in a regional perspective] 57
Economic Burden of Rheumatoid Arthritis in Italy: Possible Consequences on Anti-Citrullinated Protein Antibody-Positive Patients 56
Economic burden of human papillomavirus-related diseases in Italy 56
How can the results of Health Technology Assessment (HTA) evaluations applied to vaccinations be communicated to decision-makers and stakeholders? The ISPOR Rome Chapter Project 55
Cost-effectiveness analysis of universal human papillomavirus vaccination using a dynamic bayesian methodology. The BEST II study 55
The Effect of Herd Immunity in Different Human Papillomavirus Vaccination Strategies: An Economic Evaluation of the Best Ii Study 54
Reply to comment on Cost of poor adherence to anti-hypertensive therapy in five European country 54
From Prioritization to Universal Treatment: Successes and Challenges of Hepatitis C Virus Elimination in Italy 53
Economic aspects in the management of diabetes in Italy 53
Economic effects of treatment of chronic kidney disease with low-protein diet 52
Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective? 51
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer. 51
La dinamica demografica 51
Burden of disease of Alzheimer disease in Italy: a real-world data analysis 50
Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate. 49
A novel method to value real options in health care: the case of a multicohort human papillomavirus vaccination strategy 49
Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective 48
La dinamica demografica 48
Evaluation of quality of life and emotional distress in endometrial cancer patients: a 2-year prospective, longitudinal study 47
Cost-Effectiveness Analysis of Nirsevimab for the Prevention of Respiratory Syncytial Virus among Italian Infants. 44
Cardiotoxicity Related to Long-Term Trastuzumab Therapy in Metastatic Breast Cancer: The Potential Role of Treatment Duration and Cardiac Risk Factors. 43
Will the COVID-19 pandemic affect HCV disease burden? 42
Transforming PAH care in Italy: a clinical and economic evaluation of sotatercept add-on therapy. 41
Cost-Estimation Model of Prevented Recurrences with Atezolizumab in Early Non-Small-Cell Lung Cancer in Italy 37
Analisi di costo-efficacia di Brentuximab Vedotin + CHP in pazienti con linfoma anaplastico a grandi cellule sistemico [Cost-effectiveness of Brentuximab Vedotin plus chemotherapy as frontline treatment of systemic anaplastic large cell lymphoma in Italy 36
Time trade-off procedure for measuring health utilities loss with human papillomavirus-induced diseases: a multicenter, retrospective, observational pilot study in Italy 34
Horizon scanning and drug expenditure for rare diseases: three-year predictive model in Italy 2025-2027 27
Cost-effectiveness of cenobamate as a therapeutic alternative for the treatment of focal epilepsy in adults with inadequate seizure control 26
Totale 8.915
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.311
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.311
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20217 0 0 0 0 0 0 0 0 0 0 1 6
2021/202250 4 1 2 4 4 4 5 4 5 3 5 9
2022/202376 9 4 3 6 9 16 0 5 17 1 6 0
2023/2024517 1 8 1 5 8 2 1 10 1 1 146 333
2024/20252.515 111 218 99 179 152 109 128 203 189 247 239 641
2025/20265.470 559 753 721 489 358 253 463 297 611 444 522 0
Totale 9.129